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A B S T R A C T
One of the objectives of the Adolescent Brain Cognitive Development (ABCD) Study (https://abcdstudy.org/) is
to establish a national longitudinal cohort of 9 and 10 year olds that will be followed for 10 years in order to
prospectively study the risk and protective factors influencing substance use and its consequences, examine the
impact of substance use on neurocognitive, health and psychosocial outcomes, and to understand the re-
lationship between substance use and psychopathology. This article provides an overview of the ABCD Study
Substance Use Workgroup, provides the goals for the workgroup, rationale for the substance use battery, and
includes details on the substance use module methods and measurement tools used during baseline, 6-month and
1-year follow-up assessment time-points. Prospective, longitudinal assessment of these substance use domains
over a period of ten years in a nationwide sample of youth presents an unprecedented opportunity to further
understand the timing and interactive relationships between substance use and neurocognitive, health, and
psychopathology outcomes in youth living in the United States.
1. ABCD study substance use workgroup: introduction & overview
One of the objectives of the NIH-initiative, the Adolescent Brain
Cognitive Development (ABCD) Study, is to establish a national, mul-
tisite, longitudinal cohort study to prospectively examine the youth
from childhood (ages 9–10) through adolescence to examine the risk
and protective factors influencing the trajectories of substance use and
its consequences, examine the impact of detailed patterns of substance
use on neurocognitive development, health and psychosocial outcomes,
and to study the interactive relationship between substance use and
psychopathology in youth (https://abcdstudy.org/). The goal of this
article is to provide an overview of the ABCD Study Substance Use
Workgroup goals, rationale for the substance use battery, and detailed
methods of the battery in order for the scientific community to achieve
improved harmonization in substance use assessment, which have
varied widely, especially in measurement of frequency/quantity pat-
terns of use (Conway et al., 2014).
The Substance Use module was developed for the ABCD Study by
the Substance Use Workgroup, comprised of experts on assessment of
substance use quantity and frequency patterns, SUD diagnostic
https://doi.org/10.1016/j.dcn.2018.02.007
Received 7 April 2017; Received in revised form 1 February 2018; Accepted 16 February 2018
⁎ Corresponding author.
E-mail address: medinak@uwm.edu (K.M. Lisdahl).
Developmental Cognitive Neuroscience 32 (2018) 80–96
Available online 21 February 2018
1878-9293/ © 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license 
(http://creativecommons.org/licenses/BY-NC-ND/4.0/).
T
interviews, influences on substance use risk, and dimensional assess-
ment of substance use problems and consequences in adolescents. The
Substance Use Workgroup Co-Chairs are Drs. Mary Heitzeg (University
of Michigan) and Krista Lisdahl (University of Wisconsin-Milwaukee).
The Substance Use Workgroup members include Drs. Kevin Conway
(National Institute on Drug Abuse), Sarah Feldstein Ewing (Oregon
Health and Science University), Raul Gonzalez (Florida International
University), Sara Jo Nixon (University of Florida), Devin Prouty (SRI
International), Kenneth Sher, (University of Missouri), Susan Tapert
(University California San Diego), and Gordon Willis (National Cancer
Institute).
In determining methods and constructs to measure, the workgroup
considered the ABCD Study aims and requested methodology outlined by
the ABCD Study NIH funding opportunity announcement (https://grants.
nih.gov/grants/guide/rfa-files/RFA-DA-15-015.html). The workgroup met
weekly or biweekly and identified three primary areas to be measured: 1)
factors impacting risk of substance use; 2) assessment of detailed substance
use patterns; and 3) consequences of substance use. Constructs within these
domains were identified by the workgroup utilizing member input, litera-
ture review, and consultation with instrument authors and external experts.
During the process of finalizing the battery the workgroup prioritized in-
struments that demonstrated sound psychometric properties, fit the long-
itudinal design, were developmentally appropriate, reduced participant
burden, were open-access, and could be administered by computer. In order
to improve cross-study harmonization, if an instrument fit these criteria,
priority was given to instruments provided by PhenX (https://www.
phenxtoolkit.org/) Patterns of Substance Use module for adolescents
(module #510301), the Monitoring the Future (MTF) Study (http://www.
monitoringthefuture.org/) (Institute for Social Research and U.o.M.
Monitoring the Future, 2010), the Population Assessment of Tobacco and
Health (PATH) Study (https://pathstudyinfo.nih.gov/UI/HomeMobile.aspx)
(Hyland et al., 2016), and the National Consortium on Alcohol and Neu-
rodevelopment in Adolescence (NCANDA) Study (http://ncanda.org/)
(Brown et al., 2015) (see Table 1 for instrument overlap identification).
Further, great care and consideration was put into organizing a gating
structure to avoid exposing non- or low-using children to novel substances
(see “heard of” section below and Table 1 for gating details). After devel-
oping the draft protocol, the workgroup received and integrated feedback
from the NIH advisors and the ABCD Study Coordinating Center, and pi-
loted the protocol at multiple sites with 9–10 year olds to ensure youth
comprehension, confirm data quality and timing. Consistent with the goals
of the ABCD Study, curated data and detailed data dictionaries, including all
the substance use measures, will be released yearly to the NIMH Data Ar-
chive (NDA; https://data-archive.nimh.nih.gov/) (for further data sharing
details, see https://abcdstudy.org/scientists_data_sharing.html and the
ABCD Study overview paper included in this special issue).
2. Background and rationale
2.1. Substance use: initiated during adolescence
One of the goals of the ABCD Study is to characterize youth prior to
the initiation of significant substance use. Adolescence is a period of
ongoing neurodevelopment that is linked with an increase in risk-taking
behaviors, including the onset of substance use (Casey et al., 2008;
Eaton et al., 2006; Gardner and Steinberg, 2005; Casey et al., 2000;
Giedd et al., 1996; Gogtay et al., 2004; Lenroot and Giedd, 2006; Sowell
et al., 2004, 1999, 2002; Mills et al., 2014; Schmitt et al., 2014;
Houston et al., 2014). Initiation of drinking alcohol (beyond a sip) and
use of most illicit substances typically begins in the early teen years,
although high-risk demographic communities report initiating use
during the elementary and early middle school years (Feldstein Ewing
et al., 2015). In the U.S., among 8th graders (13–14 year olds), lifetime
use of alcohol (22.8%), electronic cigarettes (17.5%), cannabis (12.8%),
tobacco cigarettes (9.8%) inhalant (7.7%), prescription amphetamines
(5.7%) and prescription tranquilizers (3.0%) are the most commonly
used substances (Johnston et al., 2017). Data is unavailable for 8th
graders, but an alarming 18% of 12th graders have used any prescrip-
tion drug and 7.8% of 12th graders report non-medical use of pre-
scription pain relievers (OxyContin, Percocet, Vicodin, Fentanyl)
(Johnston et al., 2017). The latter is a particularly important area, given
increase risk of developing an opiate use disorder associated with
adolescent exposure, significant barriers to treatment, and alarming
rate of overdose deaths in adolescents (Liebling et al., 2016; McCabe
et al., 2016; Rudd et al., 2016). Caffeine use is very common in youth,
with 73.9% of 6–11 year olds consuming caffeinated food or beverage
on any given day within the past week and adolescents (aged 12–17
years old) consuming an average of 50mg per day (Ahluwalia et al.,
2014; Ahluwalia and Herrick, 2015).
It is notable that detailed data on substance use patterns in 9- and
10- year olds is less frequently reported, as the youngest age US na-
tional surveys assess is 12 or 13 years old [e.g., the MTF (Johnston
et al., 2017; Institute P.P.R., 2012) begins the assessment in 8th grade
(typically 13–14 years old) while the National Survey on Drug Use and
Health (Quality C.f.B.H.S.a., 2014) begins at age 12]. Data that are
available for youth younger than 12 comes from state assessments
(Donovan, 2007), such as the Texas School Survey of Drug and Alcohol
Use, which measures substance use in youth attending grades 4–6
(Institute P.P.R., 2012). This survey reports lifetime use for the fol-
lowing drug categories in 4th graders: alcohol (12.7%), nicotine (2.8%),
cannabis (0.8%), and inhalants (liquids, sprays and gases that people
sniff or inhale to get high) (11.1%) − other drug categories were not
assessed. This survey also revealed that a significant portion of 4th
graders report that they never heard of cannabis (26.1%), inhalants
(16%), nicotine (6%), and alcohol (3.6%). Taken together, data sug-
gests that youth may initiate first sipping or trying substances in late
childhood (as young as 9), and incidents of substance use initiation
increase from late childhood into early adolescence. Notably, although
some youth may be sipping alcohol or trying tobacco, the vast majority
of 9 and 10 year olds are substance-naïve and indeed may not have
heard of several drug categories. Thus, studies assessing this age group
need to avoid exposing substance-naïve youth to new substance use
concepts.
2.2. Factors impacting substance use risk in youth
As stated above, one area identified by the Substance Use
Workgroup to measure is factors that influence risk of substance use
initiation, substance use trajectories, and substance use consequences,
such as early sipping alcohol or puffing tobacco, acute initial subjective
response, drug curiosity and intentions to use, peer substance use,
parental rules, and availability of substances.
Community samples have shown that up to a third of 8- and 9-year
olds report sipping alcohol (Donovan and Molina, 2013; Jackson et al.,
2013), demonstrating that very early substance experimentation begins
in late childhood. Studies have found that early sipping predicted
drinking onset (i.e., consuming full alcohol drinks) by age 14 (Donovan
and Molina, 2011). Similarly, Jackson and colleagues (Jackson et al.,
2015) found that sipping alcohol prior to 6th grade predicted drinking a
full drink, getting drunk, and drinking heavily (i.e., 3 or more drink
equivalents on an occasion) by 9th grade, even after controlling for a
range of etiologically relevant environmental and individual difference
covariates. In contrast to the literature on alcohol, which sometimes
operationalizes determinants of a sip and having a full drink as distinct,
the field of nicotine has not tended to make this distinction. With few
exceptions (Okoli et al., 2008; Alexander et al., 1999), studies rarely
distinguish between having had a puff and having had one or more
cigarettes and data are generally missing on interim levels of progres-
sion from a puffs to first cigarette or to regular smoking. Even less is
known about the progression of trying a puff or taste of cannabis to
more regular experimentation. Closely assessing initial tobacco or
cannabis use could help to both characterize the progression of
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substance use across substances as well as help to determine variables
key to such progression.
Another important factor to measure is individual acute subjective
response to early substance experimentation, such as level of response
to alcohol, which has been found to predict risk of developing alcohol
related consequences in teens (Schuckit et al., 2008) and alcohol use
disorders in adulthood (Trim et al., 2009). Early experiences with to-
bacco are also thought to be indicators for the development of sub-
stance use disorders, thus representing an important area of youth and
adolescent research (Haberstick et al., 2011; Perkins et al., 2009;
Pomerleau et al., 1998). Therefore, if one wants to chart the course of
drinking or drug use developmentally, starting with the earliest ex-
periences of alcohol and drug use experimentation provides important
information about substance related risk.
Risk for the transition from initiating to the emergence of problem
substance use in adolescence is influenced by a variety of factors. For
example, youth who exhibit susceptibility cognitions (intentions to use
or curiosity about drugs) (Pierce et al., 1996) are twice as likely than
youth who do not see substance use this way to start smoking cigarettes
during adolescence (Choi et al., 2001; Nodora et al., 2014; Strong et al.,
2015). Recent research suggests that risk may extend to other tobacco
products as well (Trinidad et al., 2018). In addition, parenting, home
environment, neighborhood factors such as alcohol and drug avail-
ability, and peer influence have all been shown to impact substance use
onset and outcomes (Buu et al., 2009; Curran et al., 1997; Dielman
et al., 1993; Marshal et al., 2003; Trentacosta et al., 2009). The Culture
and Environment module of the ABCD protocol covers many of these
potential influences on substance use, including parental monitoring,
family environment and conflict, and neighborhood safety and crime.
In addition to these domains, the ABCD substance use module captures
low level substance use, acute subjective response, intentions to use,
peer substance use, parent perception of the availability of substances
in the neighborhood, and parent rules about substance use. Beginning
at the one-year follow up, additional measures will be added to assess
the youth’s perceived harm of substance use, disapproval of substance
use, and substance-related expectancies. Thus, the ABCD substance use
module that was developed measures important predictors of early
substance use and escalation to SUDs.
2.3. Assessment of substance use patterns & impact on neurocognition
Another area of focus the Substance Use Workgroup identified is
detailed measurement of substance use patterns, including detailed
quantity, frequency, route of administration, and co-use patterns. This
information is critical in order to complete one of the aims of the ABCD
Study: to characterize the impact of substance exposure on adolescent
neurocognitive development. Adolescents demonstrate a greater impact
of substance use on neurocognitive outcomes (Volkow et al., 2014).
Alcohol has historically been the most commonly used substance in
adolescents (Johnston et al., 2017) and converging lines of evidence
reflect that repeated alcohol use during adolescence, especially binge
drinking, has been associated with poor neurocognitive outcomes such
as brain structural and function abnormalities and reduced memory,
visuospatial skills, attention, and executive function in adolescents
(Lisdahl et al., 2013; Jacobus et al., 2015; Nguyen-Louie et al., 2016;
Pfefferbaum et al., 2016; Brumback et al., 2016; Meruelo et al., 2017;
Squeglia et al., 2015; Müller-Oehring et al., 2017; Sullivan et al., 2016;
Whelan et al., 2014). Alcohol hangover symptoms not only reflect an
immediate consequence of excessive consumption that causes distress
in the drinker (McKinney, 2010), they also uniquely predict acute
cognitive impairment in adults (Ling et al., 2010), relate to worsened
neurocognition in adolescents (McQueeny et al., 2009; Squeglia et al.,
2009), and prospectively predicts later alcohol use disorder onset in
adults (Piasecki et al., 2005). Of particular relevance to ABCD are
findings that suggest that the studies examining pathophysiology of
hangover in adults reveal that it likely involves a neuroinflammatoryTa
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process (Penning et al., 2010; Verster, 2008), that may be similar to that
observed in alcohol-related brain damage (esp. in frontal and hippo-
campal regions) in rodent models (Crews and Nixon, 2009). That is,
hangover may represent an index of alcohol-related neurotoxicity that
is associated with more persistent cognitive deficits.
Cannabis is the second most commonly used drug, with 35.6% of
12th graders using it in the past year (Johnston et al., 2017). Early
adolescent cannabis (before age 17) use is strongly correlated with
substance use and the abuse of other illicit drug use in youth (Agrawal
et al., 2004). While there is still some degree of debate (National
Academies of Sciences E. and Medicine, 2017), converging data reflect
that at least weekly cannabis use during adolescence has been asso-
ciated with neurocognitive abnormalities, including abnormal brain
morphometry and function, lower IQ, and poorer sustained attention,
verbal memory, and executive function, especially in those with an
early age of cannabis use onset see (Lisdahl et al., 2013; Batalla et al.,
2013; Lisdahl et al., 2014; Meruelo et al., 2017; Jacobus and Tapert,
2014 for reviews). It is notable that there have been challenges to this
research in terms of the wide array of metrics, lack of measurement of
potency and content of cannabinoids [e.g., tetrahydrocannabinol
(THC), cannabidiol (CBD)], lack of control of polysubstance use
(especially alcohol and nicotine), and the majority are cross-sectional
studies, making it difficult to resolve the temporal sequencing of sub-
stance exposure and neurocognitive deficits.
Nicotine is the third most commonly used substance by adolescents
and use of electronic cigarettes has become twice as popular as tradi-
tional tobacco products (Johnston et al., 2017). Concomitantly, e-ci-
garettes have been found to increase the risk for transitioning to more
traditional tobacco cigarettes (Wills et al., 2016). Although acute ad-
ministration of nicotine may enhance cognition in teens and young
adults, especially memory and attention (Poorthuis et al., 2009),
chronic use has been linked with attention and working memory defi-
cits in teens (Goriounova and Mansvelder, 2012; Wagner et al., 2013;
Jacobsen et al., 2005; England et al., 2017). Acute withdrawal from
nicotine in adolescent users has also been associated with abnormal
reward processing (Sweitzer et al., 2016), working memory (Falcone
et al., 2014; Merritt et al., 2012), and verbal memory (Jacobsen et al.,
2007) fMRI tasks, highlighting the necessity to measure last use of ni-
cotine prior to neurocognitive assessment.
Human and preclinical evidence demonstrates that other illicit
substances are linked with neurocognitive deficits in adolescents and
young adults, including cocaine (Cannizzaro et al., 2014; Nuijten et al.,
2016; Kaag et al., 2016, 2014; Marhe and Franken, 2014; Rose-Jacobs
et al., 2011; Lundqvist, 2010; Meade et al., 2015; Fernández-Serrano
et al., 2010; Sim et al., 2007; Rahman and Clarke, 2005; Kober et al.,
2016; Verdejo-Garcia et al., 2015; Moreno-López et al., 2015; Ide et al.,
2014; Tau et al., 2014; Albein-Urios et al., 2014; Ernst et al., 2000;
Mayer et al., 2013), methamphetamine (Buck and Siegel, 2015; Cuzen
et al., 2015; King et al., 2010; Scott et al., 2007), MDMA or ecstasy
(Medina et al., 2005; Medina and Shear, 2007; Costa et al., 2014; Price
et al., 2014; Downey et al., 2015; Halpern et al., 2011; Scholey et al.,
2011; McCann et al., 2014, 2008; Jager et al., 2008; de Win et al.,
2008), inhalants (Takagi et al., 2011a, 2011b, 2014; Scott and Scott,
2012, 2014), heroin (Zeng et al., 2013; Lundqvist, 2010; Ornstein et al.,
2000; Fernández-Serrano et al., 2010), cathinones (Albertson et al.,
2016; Patrick et al., 2016), ketamine (Chen et al., 2015; Nagy et al.,
2015; Tang et al., 2013; Sun et al., 2014; Morgan et al., 2012a), gamma
hydroxybutyrate (Johansson et al., 2014; Sircar et al., 2008; Youn et al.,
2015), hallucinogens (lysergic acid diethylamide, phencyclidine,
peyote, mescaline, N,N-dimethyltryptamine, alpha-methyltryptamine,
or 5-methoxy-N,N-diisopropyltryptamine, psilocybin, or salvia)
(Compton et al., 2011; Noworyta-Sokołowska et al., 2016; Graham
et al., 2010, 2012; Halpern et al., 2005; Carstairs and Cantrell, 2010;
Fickenscher et al., 2006; Mahendran et al., 2016; Ranganathan et al.,
2012), and anabolic steroids (Wallin-Miller et al., 2016; Wallin and
Wood, 2015; Hildebrandt et al., 2014; Ramos-Pratts et al., 2013;
Hermans et al., 2010). Given the common use of caffeinated beverages
in youth as young as two years old (Ahluwalia and Herrick, 2015) and
growing concern over health effects and addiction risk associated with
excessive caffeine use (Budney and Emond, 2014; Temple et al., 2017a;
Temple, 2009), examining caffeine effects on health and neurodeve-
lopment in youth is of increasing concern. Thus far, research has shown
that acute caffeine administration is generally linked with improved
cognition, although impact of chronic caffeine exposure is not well
understood (Curran and Marczinski, 2017). And at least one study re-
ported that increased caffeine consumption is linked with increased
risk-taking in adolescents (Temple et al., 2017b). Finally, prescription
stimulant medications have been linked with cognitive enhancement
(Bagot and Kaminer, 2014; Coghill et al., 2014; Tamminga et al., 2016),
while prescription anxiolytics/sedatives (Meador et al., 2011; Loring
et al., 2012; Reissig et al., 2015; Ghoneim et al., 1984) and opiates
(Allen et al., 2003; Schoedel et al., 2010) negatively impact memory,
processing speed and attention. Over the counter (OTC) cough medi-
cation containing dextromethorphan has been linked with cortical
thickness in adolescents in one study (Qiu et al., 2016), although this
outcome has yet been replicated. It is notable that the majority of these
aforementioned studies have numerous methodological weaknesses in
that they are primarily cross-sectional, have relatively small sample
sizes, lack female participants, have low power to disentangle polydrug
effects, or have not been validated in younger adolescents. Another
issue with this research to date is that polydrug use, which is common
in adolescence (Johnston et al., 2017), and co-use of substances is
rarely studied. Co-use use can uniquely impact neurocognition (Lisdahl
et al., 2013); indeed, preliminary evidence has shown that co-use of
alcohol and nicotine (Pennington et al., 2015; Schuster et al., 2016),
alcohol and cannabis (Lisdahl et al., 2013; McQueeny et al., 2009;
Medina and Shear, 2007; Bava et al., 2009; Jacobus et al., 2009; Elofson
et al., 2013; Hanson et al., 2010; Medina et al., 2007a, 2008, 2007b,
2007c), alcohol and cocaine (Medina et al., 2006; Pennings et al., 2002;
Bolla et al., 2000; Bondi et al., 1998), cannabis and nicotine (Filbey
et al., 2015; Schuster et al., 2016), and cannabis and methamphetamine
(Gonzalez et al., 2004) has been associated with unique neurocognitive
abnormalities above and beyond single substance effects in adolescents
and young adults.
In summary, numerous substances have been linked with neuro-
cognitive outcomes in adolescents. Studies have found that numerous
factors can impact findings, including total exposure (quantity/fre-
quency, including binge alcohol measures), potency and content
(especially cannabis), route of administration, outcomes such as hang-
over symptoms, and co-use of substances. Therefore, thorough mea-
surement of substance use patterns and other qualifying factors (i.e.,
potency, cannabis content, route of administration) across numerous
substances categories from childhood through adolescence is an im-
portant component of the ABCD Substance Use module. The substance
use patterns assessed by the module include alcohol, cannabis and
cannabinoids (smoked cannabis, edible cannabis, cannabis concentra-
tions, cannabis-infused alcohol, cannabis tinctures, synthetic cannabi-
noids), nicotine (tobacco cigarettes, electronic cigarettes, smokeless
tobacco, cigars, hookah, tobacco pipe, nicotine replacement), caffeine,
cocaine, cathinones, methamphetamine, 3,4-methylenediox-
ymethamphetamine (MDMA, ecstasy or molly), ketamine, gamma hy-
droxybutyrate, heroin, hallucinogens (including lysergic acid diethy-
lamide, phencyclidine, peyote, mescaline, N-dimethyltryptamine,
alpha-methyltryptamine, or 5-methoxy-N,N-diisopropyltryptamine),
psilocybin, salvia, anabolic steroids, inhalants, prescription stimulants,
prescription sedatives, prescription opioids, and OTC cough or cold
medicine. Further, the Substance Use workgroup will release the sub-
stance use patterns assessment tools to the scientific community in an
attempt to improve harmonization (see Supplemental Material)
(Conway et al., 2014).
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2.4. Consequences of substance use
Another aim of the ABCD Study is to examine factors that impact the
risk for and trajectory of SUD symptoms and consequences; other
workgroups will be measuring the numerous outcomes that may re-
present substance use consequences (i.e., cognitive, brain structure and
function, physical health, psychosocial functioning, and psycho-
pathology). Therefore, the ABCD Substance Use module will also obtain
SUD diagnosis and symptoms for alcohol, cannabis, nicotine and other
drugs. Several studies have reported that adolescent alcohol exposure is
associated with increased lifetime risk for developing an alcohol use
disorder (AUD) (DeWit et al., 2000; Winters and Lee, 2008; Grant and
Dawson, 1997; Hingson et al., 2006; McGue et al., 2001; Dawson et al.,
2008; Robins and Przybeck, 1985). Earlier age of cannabis use has also
been associated with increased risk for developing a cannabis use dis-
order (CUD); 11.5% of adults who reported having tried cannabis prior
to age 14 met DSM-5 criteria for CUD as compared to only 2.6% of
those who tried cannabis after age 18 (SAMHSA, 2013). The peak risk
of developing a nicotine use disorder (NUD) is associated with an onset
of regular nicotine use at the young age of 10, and females demonstrate
a particularly strong relationship between adolescent age of onset and
higher rates of nicotine dependence (Lanza and Vasilenko, 2015). To-
gether, these findings support the hypothesis that adolescence is a
vulnerable developmental period of high risk for development of a SUD
following early substance use exposure. Therefore, the ABCD Study will
assess DSM-5 diagnostic criteria of SUD (see the ABCD Mental Health
article in this special issue), as well as symptom counts of AUD, CUD,
NUD, and combined other illicit drug use disorder.
3. ABCD substance use battery: baseline measures
3.1. Overview, procedures, and timing of the ABCD substance use module
Youth are administered the ABCD Substance Use module by a
trained research assistant on an iPad and all questionnaires were con-
verted for electronic data capture via REDCap (Harris et al., 2009).
Parents are also administered three measures (PLUS form, availability
of substances, and parental rules about substances) on an iPad using
REDCap software. First, youth are introduced to the substance use
module, rules of confidentiality are restated, and youth are asked if they
have heard of certain substances. At this point, research assistants do
not show the youth the iPad screen (see section B for details) in order to
reduce potential exposure of novel substances. The rest of the interview
utilizes gating, in that certain questions must be answered positively or
negatively in order for the youth to receive a follow-up question or
measure (e.g., youth are only asked about substances they have heard
of and only asked about substance consequences if they have actually
used the drug; see Table 1 for gating details for each instrument). Be-
cause youth may enter the study with some prior substance use, the
baseline battery measures lifetime patterns of substance use [including
whether they used a substance, age of first- and regular-use assessment,
total lifetime quantity (in standard units), maximum lifetime dose, and
length of abstinence] of all major drug categories (see section C.1c
below for details within each drug category) (Johnston et al., 2017).
Next, recent low level use (first sip of alcohol, first puff of cannabis or
nicotine) and detailed 6-month quantity and frequency data for each of
the aforementioned substance categories are assessed with a compu-
terized modified Timeline Followback interview (TLFB) (Sobell and
Sobell, 1996; Robinson et al., 2014). For the measures assessing sub-
stance use patterns among youth actually endorsing using a drug, visual
aids are provided to improve accuracy of dosing, product identification,
and routes of administration. In subsequent waves, the TLFB interview
will be utilized to cover measurement of substance use patterns across
all ten years to ensure continuous coverage. After the patterns of use are
assessed, measures related to risk for substance use initiation and pro-
blematic substance use trajectories (e.g., intention to use, acute
subjective response, peer use, peer tolerance of use, perceived harm,
expectancies), along with substance use consequences (e.g., alcohol
hangover symptoms, symptoms of alcohol, cannabis, nicotine and drug
use disorders) are administered. The baseline substance use battery
takes an average of approximately 9min for 9 and 10 year olds to
complete; with a range between 2 and 19min (depending on processing
speed, how many substances the youth heard of, and if they were
current users) and is administered between the first section of the
neuropsychological testing and the mental health module.
It is notable that in addition to self-report of substance use, youth
undergo substance toxicology screening to measure recent substance
exposure. At baseline and year 1 follow-up sessions, biological breath,
saliva, urine and hair samples are collected from youth. This includes a
breathalyzer test (Dräger Alcotest) to measure current blood alcohol
content. In 10% of the sample or anyone reporting past year drug use,
an oral saliva sample (Dräger 5000 Drug Test Unit) is collected to test
for recent (past 1–3 days) substance use [qualitative positive/negative
results are obtained for amphetamine, benzodiazepines, cannabis (D9-
tetrahydrocannabinol), methamphetamine, cocaine, methadone, and
3,4-methylenedioxymethamphetamine (MDMA) are obtained]. If a
youth demonstrates a positive breathalyzer or oral saliva drug tox-
icology result, then the test is repeated; both test results are recorded.
Hair is being collected from all participants to provide quantitative
information about recent (past 1–3 months) substance exposure.
Samples for at-risk youth (defined at baseline and year-1 follow-up as
youth reporting intent to use cannabis or youth who have past year use
of cannabis, alcohol or nicotine) are sent to Psychemedics for quanti-
tative measurement of alcohol ethyl glucurolide, cannabis (11-Nor-9-
carboxy-tetrahydrocannabinol and cannabidiol), methamphetamine,
MDMA, amphetamine, opiates (codeine, morphone, hyrdomorph, oxy-
codone, hydrocodone), and cocaine/benzoylecgonine utilizing gas
chromatography-mass spectrometry (GC/MS/MS) and liquid chroma-
tography-mass spectrometry (LC/MS/MS). Starting at the year 1 follow-
up session, urine (NicAlert) will be collected from 10% of the sample
and in all self-reported nicotine users for semi-quantitative cotinine
(principal metabolite of nicotine) levels. All toxicology results are
coded and maintained in the data repository. Positive results for the
alcohol breath test are exclusionary. If a participant is showing signs of
intoxication, whether or not the saliva toxicology test was positive, the
participant is rescheduled for their research appointment and informed
they cannot participate while under the influence of alcohol or drugs
(excluding nicotine). (See the ABCD Biospecimens Workgroup pub-
lication in this special issue for further details.)
The parents and youth are contacted between the baseline and year
1 follow-up assessment for a 6-month follow-up phone interview to
capture new onsets of substance use (based on youth report only). Once
youth have access to private personal mobile devices (typically around
age 12), youth will be contacted directly to complete the on-line 6-
month TLFB. See Table 1 for all measures in the baseline and year 1
substance use module. Additional measures (e.g., motives for substance
use, cannabis and nicotine acute withdrawal symptoms) will likely be
added starting at year 2 follow-up sessions.
3.2. Substance use module introduction and “Heard of” questions (Youth-
Administered)
The first portion of the ABCD substance use protocol includes a brief
introduction that operationalizes the term “drug use,” repeats that all
answers are confidential, and then proceeds to ask the youth if they
have heard of specific substances. The description of drug use, con-
fidentiality, and substance use category wording was adapted for 9 and
10 year olds from existing national studies on substance use, including
the Collaborative Studies on Genetics of Alcoholism (COGA; https://
www.niaaa.nih.gov/research/major-initiatives/collaborative-studies-
genetics-alcoholism-coga-study) (Bierut et al., 2002), National Survey
on Drug Use and Health (NSDUH; https://nsduhweb.rti.org/) (Quality
K.M. Lisdahl, et al. Developmental Cognitive Neuroscience 32 (2018) 80–96
85
C.f.B.H.S.a., 2014), the PhenX Patterns of Substance Use module
(module #510301) for adolescents, and the MTF Study (Institute for
Social Research and U.o.M. Monitoring the Future, 2010).
The intention of the “heard of” substance use section is to ensure the
study does not introduce the youth to new substances and to only assess
influences on use, substance use patterns, or consequences in youth
who are already familiar with each drug category. We ask whether
youth have “heard of” alcohol (“alcohol, such as beer, wine or liquor”),
cannabis and cannabinoids (“marijuana, weed, pot, blunts, dabs, mar-
ijuana drinks or food with marijuana; fake or synthetic marijuana such
as K2 or spice”), nicotine (“tobacco products, such as cigarettes, smo-
keless tobacco, cigars, hookah, pipes, electronic or e-cigarettes), caf-
feine (‘caffeine, which is found in coffee, tea, energy drinks, and some
soda’), inhalants (“sniffing liquids, sprays or other products to get
high”), and prescription medications (“taking pills, liquids, or medica-
tions to get high in a way that your doctor or parents did not direct you
to use them” to assess stimulant, sedative/anxiolytic, and opiate pre-
scription medications and over-the-counter cough or cold medicines).
This section ends with a broad substance use question to capture any
other non-queried drug categories (“Have you heard of people using
anything else to make them feel high, dizzy or different?”). A “yes”
response to any of these opens the gating to the next level of query. For
the “other” category, research assistants check off any drugs the youth
mentions, although they do not read the options to the youth to prevent
the mentioning of novel substances [menu of options covers cocaine;
cathinones, methamphetamine; MDMA/ecstasy; ketamine; gamma hy-
droxybutyrate; opiates (heroin, opium); hallucinogens (lysergic acid
diethylamide, phencyclidine, peyote, mescaline, N,N-dimethyl-
tryptamine, alpha-methyltryptamine, 5-methoxy-N,N-diisopropyl-
tryptamine in one grouping, psilocybin and salvia separately); and
anabolic steroids]. In order to query for over-reporting, we also ask if
the youth has heard of drugs in a “bogus” drug category. If the youth
says “yes”, then the research assistant will wait a few moments and then
remind the youth about confidentiality and the need for accurate re-
sponding. If the youth has not heard of a substance, then no questions
are asked about that substance moving forward.
3.3. Substance use patterns interview: baseline
3.3.1. Lifetime substance use patterns (Youth-Administered)
At baseline, lifetime patterns of substance use are assessed in detail.
This interview was developed in order to comprehensively measure
substances that may lead to substance use disorders, or neurocognitive,
psychiatric or health consequences in youth. The lifetime interview
(created by first author based on a previously published lifetime use
interview (Lisdahl and Price, 2012)) assesses whether they ever used
each drug. If they used a substance, then follow-up questions are given
to assess 1) age of first use, 2) age of first regular use (defined at
baseline as at least weekly use for 6 months), 3) lifetime total quantity
in standard units, 4) lifetime maximum (max) dose in standard units,
and 5) last date of use (to measure length of abstinence). For any drug
used in the past 6 months, a detailed Timeline Followback interview is
also administered (see below for details). Questions are only adminis-
tered if the youth has heard of each substance.
3.3.2. Recent (Past 6 months) substance use patterns (Youth-Administered)
At baseline, a 6-months web-based modified Timeline Followback
(TLFB) is administered (developed by the first author and Dr. Bartsch).
Consistent with the original TLFB (Sobell and Sobell, 1996; Robinson
et al., 2014), the ABCD TLFB uses a calendar-based interviewer-ad-
ministered retrospective report of detailed quantity/frequency sub-
stance use patterns during the past 6 months. The TLFB is a psycho-
metrically sound instrument used to measure both alcohol and other
drugs (Sobell and Sobell, 1996) (including cannabis, nicotine, cocaine),
demonstrating reliability and validity for intervals up to 1 year (360
days) in adolescents and adults (Robinson et al., 2014; Fals-Stewart
et al., 2000). For example, reliability indices are high for measuring
cannabis use in the past year, including total joints used (0.95), greatest
number of joints on any day (.93), and number of joints used per using
day (0.94) (Robinson et al., 2014). As with the original TLFB, the ABCD
TLFB utilizes memory cues, such as holidays and personal events eli-
cited from the youth that may improve substance use recall (e.g.,
sleepovers, birthdays, parties, holidays) and these are populated onto
the web-based calendar. The site-based research assistant collaborates
with the youth to review each week of potential use, and all substance
use within that week. (See Fig. 1a–c for pictures of on-line calendar and
substance use interface.) To facilitate accurate labeling and dose
quantification, if a youth endorses using a substance, the research staff
presents visual pictures depicting standard units and modes of use (e.g.,
standard drink sizes for alcohol; for some substances, “times used” or
number of occasions are used as the standard units; research assistants
inform participants that this measures separate occasions used per day
and that an occasion is defined as a period when you used a drug and
then took a break and that the setting may change between occasions
(See Supplemental Material for TLFB Standard Unit Visual Slides). As
outlined in the next section, follow-up questions assess routes of ad-
ministration (cannabis concentrates, e-cigarettes, cocaine, metham-
phetamine, heroin), flavoring (cigarettes), typical dosing (e-cigarettes),
product content/potency (smoked cannabis, cannabis concentrate,
cannabis-infused alcohol drinks, cannabis tinctures), subjective effects
(cannabis), and where youth get their drug (cannabis) (see details
below under each substance category).
The implementation of the calendar-driven ABCD TLFB instrument
was done in JavaScript with the software packages bootstrap for design
and the full calendar plugin. The server component of this tool was
written in php and interfaces with our electronic data collection system
(REDCap) for retrieval of enrolled participant information such as
participant ID (pGUID), longitudinal event name and attempt number.
The server component is also responsible for the storage of the collected
information and the computation of derived scores. Source code of the
application is available online in the public ABCD software repository
(GitHub.com/ABCD-STUDY/timeline-followback).
For each annual follow-up, the TLFB will cover time since last as-
sessment to ensure continuous coverage of substance use patterns over
the longitudinal study. As noted above, once youth have access to
mobile technology that they can use in a confidential environment (ty-
pically by age 12), a 6-month TLFB interview will be administered by
research staff directly with the adolescent via web and/or phone. These
data will facilitate generation of overall metrics of adolescent substance
use for each endorsed category, total substance used (in standard units),
number of binge drinking episodes, drinks per binge episode, age of first
use, age of first regular use (how “regular” substance use is defined at
each time point can be determined by each scientist/authors accessing
the data by altering or creating their own TLFB scoring code, e.g.,
“regular use” can be defined as using every week, every day, etc. for
various time periods such as the past 3, 6, 12 months), dose per occa-
sion, and total number of co-use days (all substance combinations).
3.3.3. Lifetime & 6-month TLFB patterns of use: drug categories assessed
(Youth Administered)
Below is a description of each drug use category that is measured
during the lifetime patterns of use and past 6-month TLFB interviews.
These same drug categories will be assessed each year utilizing the
TLFB format. Visual aids are only provided if the youth reported using
the drug recently or in their lifetime to assist with quantification and
accurate follow-up question on type of product, typical dosing, and
route of administration.
1. Alcohol (described as “alcohol such as beer, wine, or liquor – such
as rum, vodka, gin, whiskey)”. The unit of measurement for lifetime
quantity, max drinks, and 6-month TLFB is in standard drinks
(http://rethinkingdrinking.niaaa.nih.gov), defined as 1 12-ounce
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bottle of beer or wine cooler, 1 5-ounce glass of wine, or 1 shot
(1.25 ounces) of 80-proof alcohol. Visual aids with conversations of
standard drinks are provided. On the TLFB, by measuring standard
drinks, we will also be able to measure binge-drinking episodes
(can be defined in several ways based on children’s and adolescents
body sizes (Donovan, 2009)), drinks per drinking episode, and days
of co-occurring use of other substance categories (e.g., cigarettes,
cannabis).
Fig. 1. a) Picture of initial set-up for the ABCD on-line TLFB interview.
Research assistants fill out the participant identification, session name,
number of months measured, session run, and session date. Substances
used by the youth (in this case, alcohol, tobacco cigarettes, and smoked
cannabis “MJ”) are selected. Remembered events, such as “parents out
of town” and “birthday party”, are populated onto calendar to aid recall
(also see Fig. 1c). b) Individual Substance Use Events: After the TLFB is
set up (Fig. 1a), the research assistant fills out each substance-use event
into the on-line TLFB interview by noting the substance used, standard
units, and dates of use (repeated dates are allowable). This example
demonstrates a recurring event of daily tobacco cigarette use, in the
standard unit of two cigarettes per day. c) This picture shows a com-
pleted month in the on-line ABCD TLFB interview. Example shows daily
tobacco cigarette use (two cigarettes a day; see Fig. 1b), weekend al-
cohol use (reported in standard alcohol drinks), and intermittent smoked
cannabis use (“smoked MJ”, reported in grams).
Note: the fake drug name is blacked-out to protect validity of the in-
strument.
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2. Cannabis and cannabinoids. Cannabis is a complex substance to
measure, as there are differing potency, product content (e.g., THC
and CBD), and routes of administration, which have historically not
been well addressed in cannabis research (Feldstein Ewing et al.,
2017; Lisdahl et al., 2014). Thus, the ABCD Study will track smoked
cannabis (“smoked marijuana, also called pot, grass, weed, ganja”)
assessed in grams; blunts (combined nicotine and cannabis) mea-
sured in grams; edible cannabis (“marijuana that you eat, such as
pot cookies, gummy bears, brownies”) measured in occasions;
cannabis concentrates (”marijuana oils or concentrates such as 710,
hash oil, BHO/butane hash oil, dabs, shatter, budder, honey oil;
CO2 oil, vape pen, Rick Simpson Oil/RSO, phoenix tears”) mea-
sured in occasions; cannabis –infused alcohol drinks (e.g., THC-
infused wine, beer or liquor) measured in standard drinks; cannabis
tinctures measured in ml; and synthetic cannabinoids (“fake mar-
ijuana or synthetics such as K2 and spice”) measured in occasions.
Visual aids include pictures and descriptions of different types of
cannabis, concentrates, edibles, drinks, tinctures, and synthetic
cannabinoids, including routes of administration, and typical doses.
Follow-up questions on the lifetime and 6-month TLFB interview
assess the typical strain of smoked cannabis the youth uses, typical
dose of edible cannabis (if known), type of cannabis concentrate (if
known) and typical route of administration, potency of smoked and
cannabis concentrate (if known), subjective experience of cannabis
smoking (extent of feeling “high”), cannabinoid content of cannabis
–infused alcohol and tinctures (THC, CBD or both), and source of
cannabis to measure possible diversion (Di Forti et al., 2014, 2015;
Morgan et al., 2012a, 2012b; Thurstone et al., 2011, 2013;
Salomonsen-Sautel et al., 2012; Raber et al., 2015; Loflin and
Earleywine, 2014; Michaels and Christiansen, 2012; Pierre et al.,
2016; Miller et al., 2016; Stogner and Miller, 2015; Politi et al.,
2008; Peschel, 2016; Cao et al., 2016; Barrus et al., 2016; Hopfer,
2014). As new cannabis products are likely to emerge over time, the
ABCD Substance Use Workgroup will closely attend to and monitor
trends in cannabis use, new products, and new routes of adminis-
tration throughout the longitudinal study (Borodovsky et al.,
2016).
3. Nicotine. Nicotine can be used via myriad routes of administration.
We will assess the following: tobacco cigarettes, electronic cigar-
ettes (e-cigarettes, vape pens, or e-hookah), smokeless tobacco
(chew or snus), cigars (including traditional cigars, little cigars, or
cigarillos), hookah, tobacco pipe use, and nicotine replacement
(patches, gums, nasal sprays, inhalers and lozenges). Standard of
units for the lifetime quantity, max use, and 6-month TLFB include:
cigarettes (# of cigarettes), e-cigarettes (# of occasions), smokeless
tobacco (# pinches), cigars (# of cigars or cigarellos (Sterling et al.,
2016)), hookah (# of hits), pipes (# of hits), nicotine replacement
(# of doses); visual aids will be provided for all nicotine categories.
Follow-up questions on the lifetime and 6-month TLFB will assess
whether youth typically use cigarettes with flavoring (Biswas et al.,
2016; Alsharari et al., 2015; Nonnemaker et al., 2013). Additional
follow-up questions will determine typical amount of liquid used in
e-cigarette, typical dose of nicotine, how often their e-cigarettes
contain nicotine, and type of cartridge (disposable versus re-
chargeable), which may impact total nicotine exposure (Breland
et al., 2016, 2014; Lopez et al., 2016).
4. Cocaine or crack cocaine. Cocaine and crack cocaine will be mea-
sured in total occasions (max use in mg). Follow-up questions on
the TLFB ask about typical route of administration (smoking, oral
ingestion, intranasal/snorting, injecting subcutaneous, injecting
intramuscular, injecting intravenous), how often they inject co-
caine, how often they use clean needles, and how often they smoke
it (Nuijten et al., 2016; Conti et al., 2014; Novak and Kral, 2011).
Pictures of various types of cocaine products and typical dosing are
provided.
5. Cathinones (“cathinones such as bath salts, drone, M-cat, MDVP or
meph”). The unit of measurement is in occasions (max use mea-
sured in mg). Pictures of various types of cathinones and in-
formation about mgs per package are provided.
6. Methamphetamine (“meth or crystal meth”). Methamphetamine is
measured in total occasions (max use in mg). Pictures of various
types of methamphetamine products and information about typical
dosing are provided. Follow-up questions on the TLFB ask about
typical route of administration (smoking, oral ingestion, intranasal/
snorting, injecting subcutaneous, injecting intramuscular, injecting
intravenous), how often they inject methamphetamine, how often
they use clean needles, and how often they smoke it (Novak and
Kral, 2011; Cunningham et al., 2015; Hadland et al., 2010;
Marshall et al., 2012; Al-Tayyib et al., 2014).
7. 3,4-methylenedioxymethamphetamine (“ecstasy, molly or
MDMA”). MDMA is measured in number of tablets (max use, TLFB).
Pictures of forms of MDMA/ecstasy and information about typical
dose per pill or powder are provided.
8. Ketamine (“ketamine or special K”) is measured in occasions (max
use in mg). Pictures of forms of ketamine and information about
dosing are provided.
9. Gamma hydroxybutyrate (GHB, “liquid G, or Georgia home boy”) is
measured in occasions (max use in grams) and pictures about forms
of GHB and information about dosing are provided.
10. Heroin (“heroin, opium, or junk, smack or dope”) is measured in
occasions (max use in mg). Pictures of forms of heroin and in-
formation about dosing are provided. Follow-up questions on the
TLFB ask about typical route of administration (smoking, oral in-
gestion, intranasal/snorting, injecting subcutaneous, injecting in-
tramuscular, injecting intravenous), how often they inject heroin,
and how often they use clean needles (Novak and Kral, 2011;
Hadland et al., 2010; Al-Tayyib et al., 2014).
11. Hallucinogens (described as “hallucinogen drugs that cause people
to see or experience things that are not real, such as LSD or acid,
PCP or angel dust, peyote, mescaline, DMT, AMT, or Foxy”). The
ABCD study assesses tryptamine hallucinogens, including lysergic
acid diethylamide (LSD), N,N-dimethyltryptamine (DMT), and
ayahuasca (Callaway et al., 1999; McKenna et al., 1984; McKenna
and Riba, 2015), synthetically produced tryptamine hallucinogens,
such as alpha-methyltryptamine (AMT), or 5-methoxy-N,N-diiso-
propyltryptamine (5-MeO-DIPT), which have similar effects
(Araújo et al., 2015; Meatherall and Sharma, 2003), phencyclidine
(PCP), mescaline, and peyote (Halpern et al., 2005; Carstairs and
Cantrell, 2010). Unit of measurement is in occasions; visual aids are
provided to note what types of hallucinogens they have used.
12. Hallucinogen psilocybin (“described as magic mushrooms or
shrooms”). Use of psilocybin appears more common than other
hallucinogens (Hardaway et al., 2016; Hendricks et al., 2014;
Hallock et al., 2013); psilocybin is also important to track because
of the increased attention to use of psilocybin as a form of addiction
treatment (Bogenschutz, 2017). The unit of measurement is occa-
sions (max in grams); visual aids are provided to assist with dosing
and identification of the drug.
13. Hallucinogen salvia divinorum (“salvia”) is measured in occasions;
visual aids are provided to assist in identifying salvia and mea-
suring max use (in mg).
14. Anabolic steroids (“arnolds, pumpers or roids”) is measured in oc-
casions; visual aids assist in identifying anabolic steroids and
measuring max use (in mg).
15. Inhalants (“liquids, sprays and gases that people sniff or inhale to
get high, this includes substances like poppers, correction fluid,
gasoline, glue, shoe polish, spray paints, or nitrious oxide or
whippits””). Inhalants are measured in occasions; visual aids assist
in identifying which type of inhalant used (noted in a follow-up
question, options include: poppers, correction fluid, gasoline, glue,
shoe polish, spray paint, nitrious oxide or whippits, other.)
16. Prescription stimulants (described as “stimulant drugs such as
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amphetamine, Ritalin, Adderall, ephedrine in a way a doctor did
not direct you to use them”). The unit of measurement is in number
of pills (mg for max use); visual aids assist in identifying types of
prescription stimulants and typical dosing.
17. Prescription sedative drugs (“prescription anxiolytics, tranquilizers
or sedatives in a way your doctor did not direct you to use them,
such as Xanax, Ativan, Valium, Rohypol, or sleeping pills”). Unit if
measurement is in number of pills (mg for max use); visual aids
assist in identifying types of prescription sedatives and typical
dosing.
18. Prescription opioid pain relievers. (“prescription pain relievers such
as Vicodin, Lortab, Norco, Hydrocodone, OxyContin or Percocet
that you used in a way your doctor did not direct you to use them
(this does not include OTC pain relievers such as aspirin, Tylenol or
Advil).” Unit if measurement is in number of pills (mg for max use);
visual aids assist in identifying types of prescription opiates and
typical dosing.
19. Cough or cold medicine containing dextromethorphan (DXM) (&
ldquo;Over the counter cough or cold medicine or DXM used to get
high”). Hundreds of OTC cough and cold remedies contain DXM
(Schwartz, 2005), and in 2016 4% of 12th graders reported pur-
posefully abusing OTC DXM products (Johnston et al., 2017).
Cough medicine will be measured in occasions (max use in ml) and
visual aids with various types of OTC cough or cold medicine will
be provided to assist with max dose information.
20. Over-reporting Validity Check. During the “ever used” and 6-month
TLFB questions, we added a bogus drug category with two made-up
substances to assess potential over-responding. If a youth answers
“yes” to the bogus category, the research assistant will give them a
few moments, and then remind the youth about confidentiality and
the need for accurate responding. Youth are allowed to alter any
information after this prompt.
3.4. Assessment of low level use and number of sips or puffs of cannabis and
nicotine (Youth-Administered)
3.4.1. Alcohol low level use (iSay Sip Inventory)
In order to characterize participants’ earliest sipping experience, we
adapted items used by Jackson (Jackson et al., 2015) to determine the
extent and context of sipping/tasting, which has been linked with heavy
drinking in later adolescence (Jackson et al., 2015). Specifically, at
baseline we assessed the number of times the child has sipped alcohol,
whether or not such sipping was part of a religious ceremony, the age of
onset of sipping, the context in which this occurred, the type of alcohol
it was, and whether or not the alcohol was offered to the child or
whether it was taken without permission. We also query whether or not
a full drink was consumed. The first sip qualitative information will
only be collected once per youth, although total number of past year
sips (religious and non-religious) will be collected for each youth who
has not consumed a full drink for each assessment period.
3.4.2. Cannabis and nicotine low level use
In a similar way, we query initial experiences with cannabis (first
puff or taste of marijuana) and nicotine products (e.g., first puff of a
combustible cigarette or e-cigarette, first dip of smokeless tobacco),
where they obtained the substance, when these experiences occurred,
and whether it led to further use. For cannabis, subjective experience of
feeling “high” and estimated potency (THC) is also assessed. These
measures are given if the youth heard of each substance, and reported
sipping alcohol, puffing or tasting cannabis, or puffing or chewing ni-
cotine products.
3.5. Very recent (24 h) use of caffeine, nicotine, and prescription
medications (youth- and parent- administered)
The PLUS Form will be administered to parents and youth on each
day that there is a cognitive or MRI assessment to collect detailed in-
formation on length of abstinence from nicotine, caffeine, OTC and
prescription medications (modified from NCANDA study (Brown et al.,
2015)), which may acutely impact neurocognitive performance. Parents
and youth are asked if the youth had taken any caffeine, OTC or pre-
scription medications within the last 24 h, and if so, hours since last use.
Youth are also asked time since last nicotine use within the past 24 h.
OTC and prescription medication names and dosing are also collected.
3.6. Assessment of caffeine use (Youth-Administered)
Given the availability of caffeinated beverages that are available
and consumed by youth (e.g., caffeinated sodas; caffeinated coffee
drinks; energy drinks), there is growing concern over excessive caffeine
use and development of caffeine use disorders in youth (Budney and
Emond, 2014; Cotter et al., 2013; Temple, 2009); thus, patterns of re-
cent caffeine consumption will be assessed in the ABCD Study via
modified Supplemental Beverage Questions (2004, Fred Hutchinson
Cancer Research Center shared documents). If a youth endorses hearing
of any caffeinated beverages, they are then asked the typical number of
caffeinated drinks they have per week in the past 6-months (covering
the categories of coffee, espresso, tea with caffeine, soda with caffeine,
and energy drinks). Typical serving sizes are provided (coffee=8 oz;
espresso=1 shot; tea= 8 oz, soda=12 oz; energy drink=5 oz or 2
oz for 5-h energy drink). Maximum dose (largest amount of a caffei-
nated beverage consumed in one day in the past 6 months) is also ob-
tained in ounces.
3.7. Factors impacting substance use risk: baseline
3.7.1. Intention to use (Youth-Administered)
As sated above, youth who demonstrate curiousity about trying
substances soon are more likely to start using substances during ado-
lescence (Choi et al., 2001; Nodora et al., 2014; Strong et al., 2015).
Thus, the ABCD substance use module includes a 9-item instrument to
measure the extent to which substance-naïve youth are likely to start
using alcohol, cannabis, or nicotine. The three nicotine items were used
from the Population Assessment of Tobacco and Health (PATH) Study
(Hyland et al., 2016), which expanded Pierce’s (Pierce et al., 1996)
well-established measure of cigarette susceptibility to other tobacco
products in youth and adults (ages 12 and older). The ABCD Study
Substance Use workgroup also added questions of the same format for
alcohol and cannabis to assess potential risk for initiating use across
each of these primary categories of substance exploration in this age
group. For each substance, respondents answer three questions to in-
dicate the extent to which they are curious about the substance, will try
the substance soon, and would use the substance if it were offered by a
friend. The item responses appear on a 4-point Likert scale from “very
curious,” “somewhat curious,” “a little curious,” to “not at all curious.”
The remaining scales include “definitely yes,” “probably yes,” “prob-
ably not,” and “definitely not.” Alcohol was defined as “alcohol”; can-
nabis was defined as “marijuana”; tobacco was defined as “a tobacco
product such as cigarettes, e-cigarettes, hookah, or cigars”. Youth
complete this form if they have heard of the individual substance, but
have not yet tried the substance.
3.7.2. Peer substance use (Youth-Administered)
Peer substance use and deviance is linked with risk for adolescent
substance use (Trinidad et al., 2018; Buu et al., 2009). The ABCD
protocol includes a 9-item Peer Group Deviance instrument that was
modified from the PhenX (https://www.phenxtoolkit.org/) peer sub-
stance use questionnaire, which include items from the MTF study
(Johnston et al., 2015, 1988). For each item, participants are asked the
initial stem: “how many of your friends…?” with queries for drink al-
cohol (full beer, wine or liquor), get drunk, have problems with alcohol
or other drugs, use cannabis, smoke cigarettes, use inhalants (gas, glue,
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nitrous oxide), use other drugs like cocaine, downers or LSD, and sell or
give drugs to others. The item responses are on a 5-point scale: “none,”
“a few,” “some,” “most” or “all.” One additional question was added to
address the rising use of alternative nicotine delivery devices: use other
tobacco products like e-cigarettes, pipes or hookah (Breland et al.,
2016, 2014; Lopez et al., 2016). Youth are only asked questions about
peer substance use for those substances they endorsed having heard of
at the beginning of the substance use interview.
3.7.3. Acute subjective effects (Youth-Administered)
As outlined above, acute subject effects experienced following in-
itial substance exposure predicts risk for developing SUD (Trim et al.,
2009; Haberstick et al., 2011; Perkins et al., 2009; Pomerleau et al.,
1998).
3.7.3.1. Alcohol. The PhenX (https://www.phenxtoolkit.org/) Acute
Subjective Responses to Alcohol, based on the Self-Rating of the
Effects of Alcohol (SRE) for (Schuckit et al., 2008), measures youths’
subjective effects to alcohol use following the participant’s first 5 times
of drinking, recent 3 months, and over their heaviest period of use. The
SRE has been shown to be a robust and reliable measure with regards to
the development of alcohol problems (Ray et al., 2011; Schuckit et al.,
2008). In Ray et al.’s 2011 paper, SRE scores account for as much as
25% of the variance in Alcohol Use Disorders Identification Test scores
and highly correlate (r= 0.70–0.80) with interview format scores. The
self-administered questionnaire asks participants to report about their
drinking behaviors during these time periods (first 5 times drinking,
recent 3 months, and period of heaviest use) and to list the number of
standard drinks (10–12 g of ethanol) required for the experience of each
potential effect of alcohol, including feelings of intoxication, slurred
speech, feeling unsteady or developing a stumbling gait, and unwanted
falling asleep (5).
3.7.3.2. Cannabis. The Acute Subjective Response to Marijuana scale,
developed for adolescents in the Cannabis Twin Study (Agrawal et al.,
2014, 2013), was selected to measure the participant’s subjective
response to cannabis following the youth’s first or second exposure.
Early subjective response has been linked with onset of cannabis use
disorder and cannabinoid genetics in adolescents and young adults
(Agrawal et al., 2014). The assessment asks the participant to report
his/her subjective responses on a scale from 1 “not at all,” 2
“somewhat,” 3 “a little,” to 4 “a lot,” including 11 questions about
taste, coughing, dizziness, feeling relaxed, headache, heart racing,
muscle tremble or feeling jittery, burning in throat, feeling confused,
nausea, and sensations of pleasure (i.e. rush or buzz). Youth are only
queried about each of these categories if they endorsed hearing of the
substance and using the substance at least once in their lifetime.
3.7.3.3. Nicotine. The Acute Subjective Responses to Tobacco (PhenX
(https://www.phenxtoolkit.org/) instrument has been modified from
the adult version for purposes of this ABCD Study. The self-
administered instrument assesses the participant’s subjective response
to tobacco cigarette following first exposure. The assessment has been
shown to be efficacious in capturing early smoking experiences
(Trinidad et al., 2018), subjective dizziness and related genetic
influences (Haberstick et al., 2011) and nicotinic sensitivity (Perkins
et al., 2009) in adolescents and young adults. The ABCD-adapted
version additionally captures respondents’ subjective experiences
surrounding first use of e-cigarettes or e-hookahs, smokeless tobacco
(i.e. snus or chew). The questionnaire assesses pleasant (pleasurable
buzz or rush; relaxed, dizzy) and unpleasant (e.g., did you feel nausea,
did you cough) experiences surrounding first-time tobacco use, rating
sensations on a scale from 1 “none” to 4 “intense”.
3.7.4. Availability of substances (Parent-Administered)
Increased availability of substances in the environment has
previously been linked with risk for substance use (Strong et al., 2015).
This 9-item parent-administered instrument was modified from the
PhenX (https://www.phenxtoolkit.org/) community risk and protective
factors questionnaire, based on the MTF study (Arthur et al., 2007).
Only questions regarding how easily youth may access substances in the
environment are given; these include questions regarding alcohol,
cannabis, cigarettes and other drugs. Due to the rise of electronic ci-
garette, vape pen and hookah use among adolescents (Singh et al.,
2016), a question was added regarding availability of these devices.
Because the original instrument was not validated on children as young
as 9–10 years, it was modified for administration to parents. The final
instrument asks, “if your child wanted to get< substance> , how easy
would it be for her/him to get some?” Five questions cover the fol-
lowing substances: alcohol (“beer, wine, or hard liquor”); marijuana;
cigarettes, e-cigarettes, vape pens or e-hookah; and other drugs (“a drug
like cocaine, LSD, or amphetamines”). Responses are on a 4-point Likert
scale from “very hard,” “sort of hard,” “sort of easy” to “very easy”. In
order to determine the impact of legalized medical cannabis on can-
nabis availability, an additional four questions are asked: “Is medical
marijuana (marijuana prescribed by a doctor) legal in your state?” If
yes, follow up questions are asked regarding how many friends or fa-
mily have a prescription; how easy it would be for the child to get a
prescription for medical marijuana; or how easy it would be to get
medical marijuana from someone with a prescription. All parents fill
out this instrument.
3.7.5. Parent rules regarding use (Parent-Administered)
Parental monitoring and enforcing rules against substance use serve
as a protective factor for adolescent substance use (Dishion et al., 2003;
Dishion and Kavanagh, 2003); therefore, the ABCD Study uses a 9-item
parent-administered instrument covers parent rules about the use of
substances in the home and enforcement of family rules. The instru-
ment was modified from the Rules on Drinking and Smoking Ques-
tionnaire (Dishion et al., 2003; Dishion and Kavanagh, 2003) used in
the Internet Surveys about you (iSay) study – a prospective study on
alcohol initiation and progression in adolescents (Jackson et al., 2015,
2014); this was expanded to include rules about cannabis for the ABCD
Study. Three questions are asked of the parent for the three primary
substances of experimentation for this age group (alcohol, cannabis,
cigarettes), beginning with a question about the rules for their child’s
use. Five response options range from “my child is not allowed to drink/
use marijuana/smoke cigarettes under any circumstances” to “I do not
set rules about my child’s drinking/marijuana use/smoking cigarettes”
with an additional response option of “I have not made rules yet about
my child drinking/marijuana use/smoking cigarettes.” If rules have
been set, two follow-up questions are designed to determine whether
penalties are enforced for violating the rules (“Are these the same rules
for all family members; Do you enforce penalties for violating family
rules about using marijuana/smoking cigarettes”). All parents fill out
this instrument.
3.8. Consequences of substance use: baseline
3.8.1. Alcohol hangover symptoms (Youth-Administered)
Hangover symptoms are linked with excessive alcohol consumption
and uniquely predict neurocognitive outcomes (McKinney, 2010;
McQueeny et al., 2009; Squeglia et al., 2009). For the ABCD Study, we
selected the Hangover Symptom Scale (HSS) (Slutske et al., 2003); this
contains 13 items surveying typical symptoms of alcohol hangover in-
cluding physical (e.g., tiredness, headache, sleep disturbance) and cog-
nitive/psychological symptoms (e.g., difficulty concentrating, anxiety,
depressed mood). Factor analysis indicates that covariation among these
symptoms are well represented by a single factor with good internal
consistency (α=0.84). As reported by 248, total scores was associated
with both alcohol-related consequences and parental alcohol problems
even after controlling for multiple consumption measures, indicating HSS
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scores were indexing more than simply “amount consumed.” Additional
evidence of the validity of this measure comes from an electronic diary
study where alcohol hangover scores were found to predict the occur-
rence of hangover the morning after drinking in a sample of 404 recent
drinkers, even after controlling for amount consumed on the prior day
(Robertson et al., 2012). Youth who report using alcohol twice over the
past 6 months will fill out this measure.
3.8.2. Symptoms of substance use disorders (Youth-Administered)
The ABCD Study Substance Use module includes symptom measures
of alcohol, nicotine, cannabis, and other drug use disorder.
3.8.2.1. Alcohol. The Rutgers Alcohol Problem Index (RAPI) is a 23-
item, self-report measure designed to assess adverse consequences of
alcohol consumption in adolescents (White and Labouvie, 1989). Prior
to the development of the RAPI, existing measures included
consequences that may only manifest after lengthy and chronic
history of alcohol consumption among adults (e.g., medical
complications, loss of employment); such problems would be less
likely among adolescent alcohol users. In addition, the RAPI offers
well-established and desirable psychometrics, relatively brief
administration time, developmental appropriateness, and the
availability of analogue measures assessing other substances (see MPI
and DPI below), which will facilitate comparisons of problems across
substances. Principal component analyses resulted in a unidimensional
scale consisting of 23 items that were found to be as informative as the
full set of 52 items and that showed high internal consistency upon
initial (.92) and follow-up visits (0.93). Three-year stability coefficients
for the total sample was adequate (0.40), particularly when considering
that use trajectories may not yet have stabilized during adolescence.
Test-retest reliability among a college-aged sample is reported to be
much higher (e.g., 0.88 at 1 year) in other studies (Miller et al., 2002).
The ABCD Study employs a shorter, 18-item version of the RAPI, which
is reported to correlate very highly (0.99) with the 23-item version
(White and Labouvie, 2000, 2018). Participants are instructed to
indicate how often they experienced specific problems “within the
past 6 months” because of their alcohol drinking (e.g., “Neglected your
responsibilities”) using a 4-point Likert scale: 0 times; 1–2 times; 3–5
times; or 5+ times.
3.8.2.2. Marijuana and Other Drugs.. The Marijuana Problem Index
(MPI) (Johnson and White, 1989; Simons et al., 1998) and the Drug
Problem Index (DPI) (Johnson and White, 1989; Caldwell, 2002;
Kingston et al., 2011) are parallel versions of the RAPI designed with
the same goals in mind, but focus on problems from cannabis use and
other drug use, respectively. The MPI has high internal consistency
(> 0.85) based on several studies (Simons et al., 1998; Simons and
Carey, 2002, 2006). Detailed psychometric data for the DPI have not
been reported. The MPI and DPI used in ABCD consist of the same
instructions and 18-items as the RAPI, but any references to “alcohol”
or “drinking” are replaced with “smoking or marijuana use” or “use” for
the MPI and DPI, respectively. Both rely on a 5-point Likert scale to
indicate the number of times that a participant has experienced a given
problem: 0 times; 1–2 times; 3–5 times; 6–10 times, 10+ times. The DPI
is filled out considering all illicit drug use (aside from cannabis).
3.8.2.3. Nicotine. The ABCD Study substance use module includes 10
items from the nicotine-dependence section of the Population Assessment
of Tobacco and Health (PATH) Study (Hyland et al., 2016), which were
adopted from existing well-validated and reliable surveys designed to
assess different domains of nicotine dependence (including the
Fagerström Test for Nicotine Dependence (Pomerleau et al., 1994;
Heatherton et al., 1991), PhenX (https://www.phenxtoolkit.org/),
National Youth Tobacco Survey or NYTS (Margolis et al., 2016;
Bunnell et al., 2015), Brief Wisconsin Inventory of Smoking Motives or
B-WISDM (Adkison et al., 2016; Smith et al., 2010). These included
“How soon after you awake do you want to use tobacco?” (within 5min,
from 6 to 30min, from more than 30min to 1 h, after more than 1 h but
less than 24 h, and I rarely want to use tobacco; (Fagerström/PhenX/
NYTS), “Do you ever have strong cravings to use tobacco?” (yes/no),
“Have you ever felt like you really needed to use tobacco?” (yes/no), and
seven items adapted from the B-WISDM. For these items, respondents
indicated on a 5-point Likert scale (from “not true of me at all” to
“extremely true of me”) their level of agreement for each of the following
statements: “I frequently crave tobacco,” “My tobacco use is out of
control,” “Using tobacco really helps me feel better if I’ve been feeling
down,” “Using tobacco helps me think better,” “I would feel alone
without my tobacco,” and “I usually want to use tobacco right after I
wake up.” Recent analyses reported by Strong et al. Strong (Strong et al.,
2018) supports the psychometric validity of the nicotine dependence
measure among adolescent and adult users in the PATH Study. Youth fill
out the RAPI, MPI, DPI and Nicotine Dependence Severity questionnaires
if they heard of each substance and have used each substance two or
more occasions in the past 6 months. This threshold increases to three or
more occasions if a participant is 12 years of age or older. It is also
important to note that the Kiddie Schedule for Affective Disorders and
Schizophrenia (KSADs) assesses several major past and present substance
use disorder diagnostic criteria [including alcohol, cannabis, stimulant
(amphetamine-type), cocaine sedative, opioid, hallucinogen,
phencyclidine (PCP), and inhalant use disorders] (see the ABCD Mental
Health Workgroup article in this special issue).
3.9. 6- And 18- month follow-up to catch new onset of use
As briefly described above, until youth have access to private per-
sonal mobile devices (typically around age 12), youth and their parents
will be called every six months (so at 6 months, and 18 months). First
the youth are reminded about confidentiality and asked if they are in a
private, quiet place where no one else can hear the conversation. Next,
“heard of” questions are repeated for alcohol, cannabis products, ni-
cotine products, inhalants, prescription anxiolytics, prescription sti-
mulants, prescription opiates, OTC cough medication, and “anything
else to make you feel high”. If they have heard of a substance, they are
asked if they have used that substance within the past 6-months, past
month or past week to track recent onset of new substances between in-
person assessments. Because youth are likely to be using parent phones,
response options are limited to yes/no format to maximize privacy.
Once youth have access to mobile technology that they can use pri-
vately (typically by age 12), the initial 6-month and 18-month phone
interview will be replaced with a more detailed 6-month TLFB inter-
view (covering all aforementioned drug categories in section C.3) will
be administered by research staff directly with the adolescent via web
and/or personal cell phone.
4. ABCD substance use battery: future follow-up assessments
Beginning at year one follow-up, additional questionnaires will be
added to the ABCD Substance Use module to supplement the afore-
mentioned baseline measures. These will include measures to assess
additional constructs that may influence substance use initiation and
onset of SUD in youth.
4.1. Factors impacting substance use risk: year 1 follow-up
Additional inventories will be added to the baseline interview at
year 1 follow-up:
4.1.1. Peer tolerance of substance use (Youth-Administered)
This 16-item instrument is from the PhenX (https://www.
phenxtoolkit.org/) peer substance tolerance of substance use, which is
based on items from the MTF study (Johnston et al., 2015, 1988) and
modified for the ABCD Study to include additional low-level use items
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and additional items measuring cannabis, e-cigarettes, smokeless to-
bacco, inhalants, and prescription drugs (most commonly used sub-
stances in youth (Johnston et al., 2017) as well as an “other drug” ca-
tegory (cocaine, heroin or methamphetamine). For each item,
participants are asked the initial stem question, “How do you think your
CLOSE FRIENDS feel (or would feel) about YOU doing each of the
following things”. The instrument covers trying alcohol (one or two
drinks, taking one or two drinks nearly every day, having five or more
drinks once or twice each weekend), cannabis (trying marijuana once or
twice, smoking marijuana occasionally, smoking marijuana regularly),
cigarettes (trying one or two, smoking occasionally, smoking one or
more packs of cigarettes per day), e-cigarettes (using regularly), smo-
keless tobacco (using regularly), inhalants (trying once or twice), trying
prescription pain, sedative, and stimulants in a way a doctor did not
direct you (once or twice), and trying “other drugs like cocaine, heroin
or methamphetamine”. Youth are administered individual items if they
have heard of the substance.
4.1.2. Perceived harm of substance use (Youth-Administered)
This 16-item instrument was modified the Perceived Harm of
Substance Use survey, which is based on items from the MTF study and
correlated with adolescent substance use (Johnston et al., 2015;
Johnston et al., 1988) and modified for the ABCD Study to include
additional low-level use items and additional items measuring can-
nabis, e-cigarettes, smokeless tobacco, inhalants, and prescription drugs
(most commonly used substances in youth (Johnston et al., 2017)). For
each item, participants are asked the initial stem question, “The next
questions ask for YOUR opinions on the effects of using certain drugs
and other substances. How much do you think people risk harming
themselves (physically or in other ways) if they…”. The instrument
covers the same substances and dosing as outlined above (Peer Toler-
ance of Substance Use). Youth are administered individual items if they
have heard of the substance.
4.1.3. Expectancies (Youth-Administered)
4.1.3.1. Alcohol. Alcohol expectancies are assessed with the Alcohol
Expectancy Questionnaire- Adolescent, Brief (AEQ-AB (Brown et al.,
1987; Stein et al., 2007)). This 7-item questionnaire was based on the
AEQ-A, demonstrates two factors (general positive and general
negative; accounting for 46.2% of the variance), has good internal
consistency (0.49–0.51), and demonstrated validity in predicting
adolescent drinks per week and average number of drinks per heavy
drinking day (Stein et al., 2007).
4.1.3.2. Cannabis. The Marijuana Effect Expectancy Questionnaire-
Brief (MEEQ-B (Torrealday et al., 2008)) is used to measure cannabis
related expectancies in youth and is based on the original MEEQ
(Schafer and Brown, 1991). Some wording modification was conducted
(removing the sexual item) due to the young age of the ABCD cohort.
This 6-item measure has demonstrated two overall factors (positive
effects and negative effects) accounting for 52% of the variance, good
internal consistency (0.42.60), and predictive validity for cannabis use
in youth (Torrealday et al., 2008).
4.1.3.3. Nicotine. The ABCD Study uses the Adolescent Smoking
Consequences Questionnaire (ASCQ) to assess nicotine expectancies,
which was developed on youth aged 11–19 years old, demonstrating
excellent reliability, a latent factor structure of seven factors, and
predictive validity for intention to smoke and smoking behavior (Lewis-
Esquerre et al., 2005). The ASCQ was modified to create a short version
of 7-items, choosing items that loaded most heavily (0.70–0.91) on six
factors [boredom reduction factor (“during the day, smoking can help
kill time if there is nothing to do”), negative affect reduction factor
(“cigarettes help with concentration”, “when someone is sad, smoking
helps him or her feel better”), negative physical feelings factor
(“smoking will make a person cough”), negative social impression
factor (“smoking makes people look ridiculous or silly”), social
facilitation factor (“parties are more enjoyable when a person is
smoking”), taste/sensorimotor manipulation factor (“the look and feel
of a cigarette in the mouth is good”)] that significantly predicted
adolescent smoking (Lewis-Esquerre et al., 2005).
5. Conclusions
The purpose of this article was to provide an overview and detailed
account of the ABCD Study (https://abcdstudy.org/) Substance Use
module. The Substance Use module is administered to youth and parents
at the baseline research session, 6-month phone interviews, and in-
person year 1 follow-up sessions. The module covers detailed substance
use patterns, factors impacting substance use risk, and consequences of
substance use in youth. In assembling the battery for ABCD, we at-
tempted to balance a number of competing demands including subject
burden, psychometric properties, comprehensiveness, developmental
appropriateness, timing, nonreactivity (e.g., not have our assessment
procedures affect future substance use behaviors), and use in other stu-
dies. The battery presented above reflects those considerations with the
recognition that one of the ABCD Study’s focus is on the effects of sub-
stance use on brain development and neurocognition with the attendant
need to assess drug exposures in as much detail as possible with respect
to the specific substance, quantity/frequency, dosage, potency, and route
of administration. Consequently, considerable time was spent developing
a detailed lifetime use and TLFB interviews that took these parameters
into consideration. However, we are mindful of the fact that at the initial
stages of the ABCD Study, drug exposures are likely to be minimal in this
young cohort; thus, we included measures designed to be sensitive to
low-level exposures (e.g., sipping alcohol, first puffs of cannabis and
nicotine) in order to be able to track the trajectories of substance in-
volvement for all participants. Similarly, substance use does not arise in a
vacuum so we are attentive to those social/interpersonal (drug avail-
ability, descriptive norms, family rules) and individual (e.g., outcome
expectancies) that presage initial and later use. At the same time, for that
small minority of participants who do engage in early substance use (i.e.,
assessed at baseline), we are poised to capture both acute drug effects
(e.g., subjective effects), various harms (e.g., individual, neurocognitive,
and social consequences) as well as SUD symptomatology and diagnosis
(see ABCD Mental Health module). In this way, we hope to be able to
portray substance use and its correlates as comprehensively as possible
and track its course developmentally in combination with brain devel-
opment and other important variables.
In summary, detailed, on-going prospective, longitudinal assessment
of these domains over a period of ten years in a diverse, nationwide
sample of youth in the United States presents an unprecedented oppor-
tunity to examine the risk and protective factors influencing the onset and
sequela of substance use and its consequences, the impact of detailed
patterns of substance use (including co-use and polydrug use) on neuro-
cognitive development, health and psychosocial outcomes, and to further
understand the timing and interactive relationship between substance use
and psychopathology in youth that live in the United States.
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